Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry

Ballanti, P.; Minisola, Salvatore; Pacitti, M. T.; Scarnecchia, L.; Rosso, R.; Mazzuoli, G. F.; Bonucci, E.

doi:10.1007/bf01623458

Cited by 127 publications

(92 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SaOS-2 cells, the gene expression ratio of OPG: RANKL has been found to increase in cocultivation experiments with RAW 264.7 cell beads if silica had been included in the hydrogel matrix , indicating a decreased osteoclastogenic activity of osteoblasts (SaOS-2) and an impaired differentiation of osteoclasts (RAW 264.7) (Thomas et al 2001;Wang et al 2012c). This conclusion is supported by the finding that the expression of the gene encoding tartrate-resistant acid phosphatase (TRAP), a marker for osteoclast differentiation (Ballanti et al 1997;Walsh et al 2003), is strongly reduced in RAW 264.7 if co-incubated with SaOS-2 embedded Fig. 9.7 3D cell printing on a morphogenetically active scaffold.…”

Section: Biosilica-alginate Hydrogelsupporting

confidence: 51%

Inorganic Polymers: Morphogenic Inorganic Biopolymers for Rapid Prototyping Chain

Müller

Schröder

Shen

et al. 2013

Biomedical Inorganic Polymers

View full text Add to dashboard Cite

In recent years, considerable progress has been achieved towards the development of customized scaffold materials, in particular for bone tissue engineering and repair, by the introduction of rapid prototyping or solid freeform fabrication techniques. These new fabrication techniques allow to overcome many problems associated with conventional bone implants, such as inadequate external morphology and internal architecture, porosity and interconnectivity, and low reproducibility. However, the applicability of these new techniques is still hampered by the fact that high processing temperature or a postsintering is often required to increase the mechanical stability of the generated scaffold, as well as a post-processing, i.e., surface modification/functionalization to enhance the biocompatibility of the scaffold or to bind some bioactive component. A solution might be provided by the introduction of novel inorganic biopolymers, biosilica and polyphosphate, which resist harsh conditions applied in the RP chain and are morphogenetically active and do not need supplementation by growth factors/cytokines to stimulate the growth and the differentiation of bone-forming cells.

show abstract

Section: Biosilica-alginate Hydrogelsupporting

confidence: 51%

Inorganic Polymers: Morphogenic Inorganic Biopolymers for Rapid Prototyping Chain

Müller

Schröder

Shen

et al. 2013

Biomedical Inorganic Polymers

View full text Add to dashboard Cite

show abstract

“…The results obtained have been compared with the assay of serum tartrate-resistant acid phosphatase activity (TRAP) [12,13], in order to assess how two different serum markers of bone resorption may reflect well-known changes in bone turnover.…”

Section: Introductionmentioning

confidence: 99%

Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone

Minisola

Dionisi

Pacitti

et al. 2002

Osteoporosis International

Self Cite

View full text Add to dashboard Cite

To assess how two different serum markers of bone resorption may reflect changes in bone turnover, we compared age- and sex-related changes in serum C-terminal telopeptide of type I collagen (betaCTx) and tartrate-resistant acid phosphatase activity (TRAP) in 136 healthy men and 184 normal women. Serum levels of the two markers were also assessed in several groups of patients of both sexes presenting with the most common metabolic and endocrine bone diseases: established osteoporosis (n = 77), primary hyperparathyroidism (n = 44), glucocorticoid excess (n = 17), chronic renal failure (n = 39), active Paget's disease of bone (n = 5), humoral hypercalcemia of malignancy (n = 3), osteomalacia (n = 3), hyperthyroidism (n = 10), post-surgical hypoparathyroidism (n = 10), acromegaly (active disease, n = 8) and Cushing's syndrome (n = 10). In men the regression of betaCTx with age showed an initial decrease in bone resorption followed by an increase thereafter, starting from the sixth decade of life. No age-related change in serum TRAP activity was observed. In women, by contrast, a slight but significant linear correlation of both serum betaCTx and TRAP with age (r = 0.223, p<0.003 and r = 0.333, p<0.0001, respectively) was found, the two markers being positively correlated (r = 0.238, p<0.002). In each class of patients the mean Z-scores of betaCTx were significantly higher than those of TRAP activity. Moreover, compared with normal subjects, serum betaCTx seems to be characterized by a superior sensitivity relative to TRAP measurement, at least in the disorders studied.

show abstract

“…3m). Histomorphometric measures of osteoclast function including osteoclast surface per bone surface (Oc.S/BS) 51 , as judged by Tartrate Acid Resistant Phosphatase TRAP staining 52 , were also unchanged ( Supplementary Fig. 3n).…”

mentioning

confidence: 76%

ATRAIDregulates the action of nitrogen-containing bisphosphonates on bone

Surface

Burrow²,

Park³

et al. 2018

Preprint

View full text Add to dashboard Cite

. CC-BY-NC-ND 4.0 International license It is made available under a was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/338350 doi: bioRxiv preprint first posted online Jun. 4, 2018; 3 Nitrogen-containing bisphosphonates (N-BPs) are the standard treatment for osteoporosis and several other bone diseases 11,12 . Certain N-BPs (pamidronate (Aredia®), zoledronate (Zometa®)) are also routinely prescribed to prevent skeletal complications in patients with multiple myeloma and with bone metastases from other malignancies, including breast and prostate cancer 13 . However, because N-BPs cause rare yet serious side-effects, such as atypical fractures and osteonecrosis of the jaw, many patients avoid taking them [5][6][7]11 , causing the number of prescriptions to plummet over 50% in the last decade 7,14 . Thus, there is a sizeable and growing need to better understand the genetic factors that might underlie the onand off-target clinical effects of the N-BPs.A goal of personalized medicine is to identify biomarkers that underlie drug responsiveness. In the case of the N-BPs, it can be said that there are limited personalization options owing to the limited number of genes implicated in the mechanism of action of N-BPs on bone. was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/338350 doi: bioRxiv preprint first posted online Jun. 4, 2018; 4 understanding of the molecular mechanisms by which N-BPs regulate the major bone cell types would be improved by further studies.To provide insight into the mechanism(s) of N-BPs action, we performed a genetic screen to identify human genes required for the anti-proliferative effects of N-BPs (Fig. 1a) Other genes identified in our alendronate haploid screen (SNTG1, PLCL1, and EPHB1) have been previously connected to N-BP action on bone cells and/or human bone diseases [28][29][30] . To systematically evaluate all "hits" we identified (i.e., the 185 genes with FDR p-value < 0.05, see Fig. 1b), we developed a computational approach utilizing a molecular biology-optimized version of PubMed (currently at ~27M records) to assess to what extent our haploid screen identified genes were cited as relevant to human studies that focus on bone (see "PubMed citation analysis" in the Methods section for details). We asked whether our alendronate haploid screen hits were mentioned in publications co-occurring with the term "bone" vs. other tissues along with identifiers of genome-wide screening, namely the strings, "GWAS" or "genome-wide" (Fig. 1c). Indeed, our alendronate screen hits were enriched in publications co-mentioning "bone" and genome-wide studies compared to control gene sets (Fig. 1d, Supplementary Table 1b). This . CC-BY-NC-ND 4.0 International license It is made available under a was not peer-reviewed...

show abstract

Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry

Cited by 127 publications

References 16 publications

Inorganic Polymers: Morphogenic Inorganic Biopolymers for Rapid Prototyping Chain

Inorganic Polymers: Morphogenic Inorganic Biopolymers for Rapid Prototyping Chain

Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone

ATRAIDregulates the action of nitrogen-containing bisphosphonates on bone

Contact Info

Product

Resources

About